Physician profile
Richard Kim
NPI 1780096602
$2,237.91
in general payments reported to CMS, 2019-2025
28 companies · $783 in 2025
The $783 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $30.94 · 2021: $92.48 · 2022: $204 · 2023: $323 · 2024: $406 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $221.01 | 2022-2025 | Gel-One Cross-Linked Hyaluronate |
| Medtronic, INC. | $210.94 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Allergan, INC. | $186.04 | 2019-2020 | |
| Si-Bone, INC. | $179.15 | 2022-2024 | |
| Boston Scientific Corporation | $165.07 | 2019-2025 | General - Pain Management |
| Integra Lifesciences Corporation | $150.37 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Exact Sciences Corporation | $148.86 | 2023-2025 | Cologuard Collection Kit |
| Fidia Pharma USA INC. | $122.36 | 2020-2025 | Triluron, Hymovis, Hyalgan |
| Pacira Therapeutics, INC. | $91.59 | 2019-2021 | |
| Spr Therapeutics, INC | $86.06 | 2024 | Sprint Pns System |
| Globus Medical, INC. | $84.82 | 2024-2025 | Senza, Captivate Vl |
| Depuy Synthes Sales INC. | $73.30 | 2021-2025 | Orthovisc, Monovisc |
| Bioventus LLC | $71.58 | 2022-2025 | Xcell, Durolane |
| Novo Nordisk INC | $70.37 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $51.70 | 2024-2025 | Mounjaro, Zepbound |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.13 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $40.92 | 2019-2024 | Euflexxa |
| Pacira Pharmaceuticals Incorporated | $30.82 | 2023-2025 | Iovera, Zilretta |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2022-2025 | Trintellix |
| Ibsa Pharma INC. | $28.76 | 2023 | Tirosint, Licart |
| Vertical Pharmaceuticals, LLC | $28.47 | 2019 | |
| Saluda Medical Americas, INC. | $22.24 | 2025 | Evoke |
| Merz Pharmaceuticals, LLC | $21.73 | 2025 | Xeomin |
| Glaxosmithkline, LLC. | $18.44 | 2025 | Shingrix |
| Mayne Pharma Commercial LLC | $14.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.81 | 2023 | Austedo |
| Kowa Pharmaceuticals America, INC. | $12.87 | 2022 | |
| Seqirus USA INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.